Dual AAV Gene Therapy for Duchenne Muscular Dystrophy with a 7-kb Mini-Dystrophin Gene in the Canine Model

• Published in: Human gene therapy Vol. 29; no. 3; p. 299
• Main Authors: Kodippili, Kasun, Hakim, Chady H, Pan, Xiufang, Yang, Hsiao T, Yue, Yongping, Zhang, Yadong, Shin, Jin-Hong, Yang, N Nora, Duan, Dongsheng
• Format: Journal Article
• Language: English
• Published: United States 01.03.2018
• Subjects: dual AAV vectors; canine model; adeno-associated virus; mini-dystrophin; dystrophin; Duchenne muscular dystrophy
• ISSN: 1557-7422
• DOI: 10.1089/hum.2017.095

Dual adeno-associated virus (AAV) technology was developed in 2000 to double the packaging capacity of the AAV vector. The proof of principle has been demonstrated in various mouse models. Yet, pivotal evidence is lacking in large animal models of human diseases. Here we report expression of a 7-kb canine ΔH2-R15 mini-dystrophin gene using a pair of dual AAV vectors in the canine model of Duchenne muscular dystrophy (DMD). The ΔH2-R15 minigene is by far the most potent synthetic dystrophin gene engineered for DMD gene therapy. We packaged minigene dual vectors in Y731F tyrosine-modified AAV-9 and delivered to the extensor carpi ulnaris muscle of a 12-month-old affected dog at the dose of 2 × 10 viral genome particles/vector/muscle. Widespread mini-dystrophin expression was observed 2 months after gene transfer. The missing dystrophin-associated glycoprotein complex was restored. Treatment also reduced muscle degeneration and fibrosis and improved myofiber size distribution. Importantly, dual AAV therapy greatly protected the muscle from eccentric contraction-induced force loss. Our data provide the first clear evidence that dual AAV therapy can be translated to a diseased large mammal. Further development of dual AAV technology may lead to effective therapies for DMD and many other diseases in human patients.